Alzheimer’s Drugs Should be No More Than $3,000 Per Year to Be Cost-Effective, Study Says

In order to be cost-effective relative to standard Alzheimer’s care, Aduhelm — the newly approved Alzheimer’s antibody — would have to cost no more than $3,000 per year, rather than the current $56,000 price tag.
Source: Drug Industry Daily